TPWA
PRME icon

Twin Peaks Wealth Advisors’s Prime Medicine PRME Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$10 – 1683
2026
Q1 		$10 Buy
+3
New +$11 ﹤0.01% 2365

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Twin Peaks Wealth Advisors's PRME Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 3 shares — an estimated $10 sold.

Twin Peaks Wealth Advisors first reported a position in PRME in Q1 2026 and held it in 1 quarter. The position peaked at $10 in Q1 2026. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 3 Prime Medicine shares in Q2 2026, an estimated $10.
  • Twin Peaks Wealth Advisors first reported a position in Prime Medicine in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Prime Medicine position peaked at $10 in Q1 2026.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.